文献速递中毒与环境急症儿科与产科急症

美国毒物中心报告的δ-8四氢大麻酚、δ-10四氢大麻酚和四氢大麻酚-O乙酸酯暴露

Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers.
PubMed 文献 · Clin Toxicol (Phila) · 2024-04-30
一句话结论2021至2022年美国毒物中心报告的δ-8四氢大麻酚等合成大麻素暴露增加89.1%,儿童误服占30.1%,38.4%为严重医学结局。

该研究分析了2021年1月1日至2022年12月31日美国毒物中心国家毒物数据系统中以δ-8四氢大麻酚、δ-10四氢大麻酚和四氢大麻酚-O乙酸酯为主要物质的5,022例暴露报告。暴露率从2021年的0.55/10万升至2022年的1.04/10万,增加89.1%。6岁以下儿童占30.1%,最常见为意外-一般原因(40.2%),主要临床效应为轻度中枢神经系统抑制(25.0%)、心动过速(23.0%)和激越(15.6%)。38.4%发生严重医学结局,10.3%入住非重症监护病房,5.3%入住重症监护病房。作者认为存在改进监管和公众教育的机会。

要点

  • 2021至2022年美国毒物中心共报告5,022例以δ-8四氢大麻酚、δ-10四氢大麻酚或四氢大麻酚-O乙酸酯为主要物质的暴露,暴露率从0.55/10万升至1.04/10万,增加89.1%。
  • 6岁以下儿童占30.1%,年龄众数为2岁(占8.9%),摄入途径占94.2%,其中6岁以下儿童中摄入占95.1%。
  • 最常见暴露原因为意外-一般(40.2%),其次为滥用(33.1%)。
  • 最常见相关临床效应为轻度中枢神经系统抑制(25.0%)、心动过速(23.0%)和激越(15.6%)。
  • 38.4%的病例发生严重医学结局,10.3%入住非重症监护病房,5.3%入住重症监护病房。

适用人群与场景

  • 2021年1月1日至2022年12月31日向美国毒物中心报告的、以δ-8四氢大麻酚、δ-10四氢大麻酚或四氢大麻酚-O乙酸酯为主要物质的暴露病例。
  • 6岁以下儿童占30.1%,年龄众数为2岁(占8.9%)。

研究设计与关键结果

  • 研究类型:基于美国国家毒物数据系统的分析;样本量5,022例;数据来源为美国毒物中心2021年1月1日至2022年12月31日的报告。
  • 暴露率从2021年的0.55/10万升至2022年的1.04/10万,增加89.1%。
  • 98.1%的病例涉及δ-8四氢大麻酚;94.3%为单物质暴露;95.9%发生在住所。
  • 摄入途径占94.2%,其中6岁以下儿童中摄入占95.1%。
  • 暴露原因:意外-一般40.2%,滥用33.1%。
  • 临床效应:轻度中枢神经系统抑制25.0%,心动过速23.0%,激越15.6%。
  • 严重医学结局占38.4%;10.3%入住非重症监护病房,5.3%入住重症监护病房。

证据类型、等级与局限

  • 证据类型:基于美国国家毒物数据系统的被动监测分析。
  • 局限:国家毒物数据系统受其被动监测设计限制。

对床旁实践的改变

  • 作者认为,这些产品具有毒性作用,且2021至2022年向美国毒物中心的报告增加;幼儿意外摄入尤其值得关注。
  • 作者认为,存在改进对这些产品的监管并配套执法的机会,以及教育公众认识其潜在毒性的机会。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Since the passage of the Farm Bill in 2018, the availability of synthetic tetrahydrocannabinols has increased, including delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate. The objective of this study is to investigate the characteristics of delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to United States poison centers from 2021 to 2022.

METHODS: National Poison Data System data were analyzed, including year, individual demographics, substance category and type, reason for exposure, highest level of health care received, and medical outcome. United States Census Bureau data were used to calculate population-based rates.

RESULTS: There were 5,022 reported cases involving delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate as the primary substance reported to United States poison centers from 1 January 2021 to 31 December 2022. The rate of exposure per 100,000 United States population increased by 89.1 percent from 0.55 in 2021 to 1.04 in 2022. Children less than 6 years old accounted for 30.1 percent of cases, with a mode at age 2 years (representing 8.9 percent of cases). Most cases involved delta-8 tetrahydrocannabinol (98.1 percent), were single-substance exposures (94.3 percent), or occurred in a residence (95.9 percent). Ingestions accounted for 94.2 percent of cases, including 95.1 percent among children less than 6 years old. The leading reason for exposure was unintentional-general (40.2 percent), followed by abuse (33.1 percent). The most common related clinical effects were mild central nervous system depression (25.0 percent), tachycardia (23.0 percent), and agitation (15.6 percent). More than one-third (38.4 percent) of cases experienced a serious medical outcome, and 10.3 percent were admitted to a noncritical care unit and 5.3 percent to a critical care unit.

DISCUSSION AND LIMITATIONS: The National Poison Data System is limited by its passive surveillance design. Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate have toxic effects, and reports to United States poison centers increased from 2021 to 2022. Unintentional ingestions by young children are of particular concern.

CONCLUSIONS: Opportunities exist to improve regulation, with accompanying enforcement, of these products and to educate the public about their potential toxicity.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Burgess A, Hays HL, Badeti J, et al. Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers. Clin Toxicol (Phila). 2024. PMID: 38686923. doi:10.1080/15563650.2024.2340115

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。